PSNL - Personalis Inc Stock Price, Fair Value and News

1.57USD-0.08 (-4.85%)Market Closed

Market Summary

USD1.57-0.08

Market Closed

-4.85%

PSNL Stock Price

View Fullscreen

PSNL RSI Chart

PSNL Valuation

Market Cap

85.7M

Price/Earnings (Trailing)

-0.93

Price/Sales (Trailing)

1.16

EV/EBITDA

-0.51

Price/Free Cashflow

-1.26

PSNL Price/Sales (Trailing)

PSNL Profitability

Operating Margin

25.59%

EBT Margin

-124.79%

Return on Equity

-76.73%

Return on Assets

-47.42%

Free Cashflow Yield

-79.54%

PSNL Fundamentals

PSNL Revenue

Revenue (TTM)

74.1M

Rev. Growth (Yr)

3.53%

Rev. Growth (Qtr)

-0.76%

PSNL Earnings

Earnings (TTM)

-92.6M

Earnings Growth (Yr)

54.75%

Earnings Growth (Qtr)

51.22%

Breaking Down PSNL Revenue

52 Week Range

1.132.60

(Low)(High)

Last 7 days

3.1%

Last 30 days

13.8%

Last 90 days

37.5%

Trailing 12 Months

-22.5%

How does PSNL drawdown profile look like?

PSNL Financial Health

Current Ratio

3.84

PSNL Investor Care

Shares Dilution (1Y)

11.02%

Diluted EPS (TTM)

-1.9

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	74.1M	0	0	0
2023	68.7M	67.1M	70.5M	73.5M
2022	79.8M	76.4M	69.0M	65.0M
2021	80.4M	82.5M	85.0M	85.5M
2020	70.3M	74.0M	76.6M	78.6M
2019	47.7M	54.7M	60.2M	65.2M
2018	16.5M	23.6M	30.7M	37.8M
2017	0	0	0	9.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Personalis Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 30, 2024	moore stephen michael	sold	-6,196	1.37	-4,523	svp and chief legal officer
Mar 01, 2024	myers woodrow a jr	bought	16,700	1.67	10,000	-
Jan 29, 2024	chen richard	sold	-720	1.37	-526	chief medical officer and evp
Jan 29, 2024	tachibana aaron	sold	-980	1.37	-716	cfo and coo
Dec 15, 2023	tachibana aaron	sold	-9,918	1.47	-6,747	cfo and coo
Dec 15, 2023	moore stephen michael	sold	-2,169	1.47	-1,476	general counsel
Dec 15, 2023	chen richard	sold	-6,920	1.47	-4,708	chief medical officer and evp
Nov 16, 2023	chen richard	sold	-977	1.04	-940	chief medical officer and evp
Nov 16, 2023	tachibana aaron	sold	-1,397	1.04	-1,344	cfo and coo
Nov 16, 2023	moore stephen michael	sold	-1,790	1.04	-1,722	general counsel

Which funds bought or sold PSNL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 08, 2024	US BANCORP \DE\	new	-	13,559	13,559	-%
May 08, 2024	Russell Investments Group, Ltd.	reduced	-4.9	-15,186	31,504	-%
May 07, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	reduced	-56.08	-56,963	25,783	-%
May 06, 2024	Parallel Advisors, LLC	unchanged	-	-10,078	24,618	-%
May 03, 2024	Wellington Shields Capital Management, LLC	reduced	-8.56	-352,418	651,027	0.12%
May 03, 2024	HOWLAND CAPITAL MANAGEMENT LLC	added	392	224,593	314,566	0.01%
May 03, 2024	GSA CAPITAL PARTNERS LLP	added	6.19	-205,000	626,000	0.05%
May 03, 2024	Baader Bank Aktiengesellschaft	sold off	-100	-16,675	-	-%
May 03, 2024	Wellington Shields & Co., LLC	reduced	-0.07	-182,869	445,655	0.15%
May 02, 2024	Nikko Asset Management Americas, Inc.	reduced	-9.79	-797,390	1,456,680	0.01%

Are Funds Buying or Selling PSNL?

Are funds buying PSNL calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PSNL

No. of Funds

Unveiling Personalis Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 29, 2024	ark investment management llc	13.61%	6,671,545	SC 13G/A
Jan 26, 2024	blackrock inc.	6.8%	3,315,268	SC 13G/A
Dec 07, 2023	jpmorgan chase & co	0.0%	0	SC 13G/A
Dec 05, 2023	tempus labs, inc.	15.8%	9,218,800	SC 13G
Feb 10, 2023	ark investment management llc	11.96%	5,500,400	SC 13G/A
Jan 31, 2023	blackrock inc.	7.7%	3,558,913	SC 13G/A
Jan 25, 2023	jpmorgan chase & co	7.6%	3,502,353	SC 13G/A
Mar 09, 2022	blackrock inc.	10.0%	4,502,224	SC 13G/A
Mar 07, 2022	lightspeed venture partners viii lp	9.16%	4,117,768	SC 13D/A
Feb 09, 2022	ark investment management llc	10.91%	4,888,115	SC 13G/A

Recent SEC filings of Personalis Inc

View All Filings

Date Filed	Form Type	Document
May 08, 2024	8-K	Current Report
May 08, 2024	10-Q	Quarterly Report
May 02, 2024	4	Insider Trading
Apr 02, 2024	DEFA14A	DEFA14A
Apr 02, 2024	DEF 14A	DEF 14A
Apr 02, 2024	ARS	ARS
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading

Peers (Alternatives to Personalis Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	186.3B	23.7B	0.67%	7.73%	42.31	7.85	-8.94%	-35.91%
A	42.5B	6.7B	-1.54%	13.33%	34.41	6.31	-2.81%	-6.58%
IDXX	41.4B	3.7B	-3.64%	3.26%	47.74	11.11	8.57%	23.94%
DGX	15.3B	9.3B	4.06%	4.31%	18.14	1.65	-3.29%	6.68%
MEDP	12.4B	2.0B	-1.35%	90.01%	39.59	6.3	25.57%	21.62%
CRL	11.9B	4.1B	-10.52%	23.52%	27.01	2.88	0.49%	-11.59%
NTRA	11.7B	1.2B	-1.92%	86.70%	-32.11	9.71	39.26%	33.08%
EXAS	10.0B	2.5B	-27.12%	-31.26%	-41.57	3.94	15.21%	53.51%
MID-CAP
NEOG	2.7B	929.2M	-4.60%	-27.46%	1.7K	2.9	28.93%	111.61%
GH	2.4B	603.7M	1.41%	-29.38%	-5.17	3.95	25.21%	30.68%
SMALL-CAP
CDNA	576.0M	275.1M	11.46%	29.10%	-3.14	2.09	-13.93%	-126.97%
ACRS	87.7M	31.1M	2.52%	-85.28%	-1.13	2.82	0.95%	19.75%
AWH	37.9M	9.2M	-	-31.11%	-2.27	4.14	11.85%	44.15%
APDN	3.7M	5.5M	858.97%	243.12%	-0.3	0.67	-68.52%	-141.15%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

Personalis Inc News

Latest updates

Personalis Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-0.8%	19,525,000	19,675,000	18,247,000	16,699,000	18,860,000	16,722,000	14,858,000	18,240,000	15,227,000	20,682,000	22,261,000	21,670,000	20,881,000	20,176,000	19,816,000	19,495,000	19,161,000	18,154,000	17,153,000	15,825,000	14,075,000
Cost Of Revenue	-3.0%	14,032,000	14,470,000	14,766,000	11,907,000	14,130,000	14,410,000	12,379,000	13,959,000	10,949,000	12,686,000	14,195,000	13,502,000	13,454,000	14,106,000	14,483,000	14,823,000	15,122,000	11,589,000	11,524,000	9,923,000	10,091,000
Costs and Expenses	-12.0%	38,405,000	43,647,000	49,040,000	42,045,000	48,685,000	48,807,000	42,117,000	46,121,000	43,533,000	40,907,000	39,952,000	36,617,000	33,371,000	33,546,000	29,469,000	28,993,000	28,786,000	25,350,000	22,883,000	19,886,000	19,506,000
S&GA Expenses	0.7%	11,602,000	11,524,000	11,971,000	12,134,000	14,097,000	17,828,000	14,781,000	15,874,000	15,486,000	13,709,000	12,140,000	11,428,000	10,421,000	10,920,000	7,793,000	7,705,000	7,274,000	6,388,000	6,056,000	5,466,000	4,170,000
R&D Expenses	-6.2%	12,771,000	13,613,000	16,738,000	17,852,000	16,573,000	16,569,000	14,957,000	16,288,000	17,098,000	14,512,000	13,617,000	11,687,000	9,496,000	8,520,000	7,193,000	6,465,000	6,390,000	7,373,000	5,303,000	4,497,000	5,245,000
EBITDA Margin	17.0%	-1.09	-1.32	-1.44	-1.48	-1.52	-1.61	-1.38	-1.13	-0.93	-0.69	-0.62	-0.54	-	-	-	-	-	-	-	-	-
Interest Expenses	0%	9,000	9,000	15,000	39,000	47,000	47,000	45,000	50,000	59,000	59,000	60,000	65,000	-	-	-	-	2,000	-	204,000	745,000	184,000
Income Taxes	40.0%	7,000	5,000	28,000	36,000	14,000	8,000	11,000	14,000	7,000	-3,000	12,000	8,000	-3,000	18,000	5,000	4,000	30,000	4,000	1,000	2,000	2,000
Earnings Before Taxes	51.2%	-12,961,000	-26,579,000	-29,070,000	-23,919,000	-28,645,000	-31,060,000	-26,481,000	-27,532,000	-28,202,000	-20,202,000	-17,658,000	-14,945,000	-12,407,000	-13,323,000	-9,540,000	-9,251,000	-9,109,000	-6,641,000	-6,884,000	-5,867,000	-5,683,000
EBT Margin	15.3%	-1.25	-1.47	-1.60	-1.64	-1.66	-1.74	-1.48	-1.22	-1.01	-0.76	-0.69	-0.61	-	-	-	-	-	-	-	-	-
Net Income	51.2%	-12,968,000	-26,584,000	-29,098,000	-23,955,000	-28,659,000	-31,068,000	-26,492,000	-27,546,000	-28,209,000	-20,199,000	-17,670,000	-14,953,000	-12,404,000	-13,341,000	-9,545,000	-9,255,000	-9,139,000	-6,645,000	-6,885,000	-5,869,000	-5,685,000
Net Income Margin	15.3%	-1.25	-1.47	-1.60	-1.64	-1.66	-1.74	-1.48	-1.23	-1.01	-0.76	-0.69	-0.61	-	-	-	-	-	-	-	-	-
Free Cashflow	-21.1%	-20,517,000	-16,942,000	-17,549,000	-13,155,000	-19,523,000	-26,300,000	-36,179,000	-37,659,000	-19,991,000	-18,851,000	-20,842,000	-30,036,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4
Assets	-13.2%	195	225	227	249	272	293	318	358	381	397	407	383	396	245	249	146	152	157	160	192	42.00
Current Assets	-17.9%	120	147	148	161	183	200	222	260	294	318	329	354	373	221	224	120	135	140	140	176	30.00
Cash Equivalents	-22.8%	44.00	57.00	72.00	97.00	87.00	89.00	84.00	87.00	92.00	106	80.00	70.00	137	69.00	133	25.00	47.00	55.00	87.00	163	20.00
Net PPE	-4.9%	55.00	57.00	57.00	59.00	61.00	62.00	61.00	48.00	31.00	20.00	18.00	14.00	11.00	12.00	13.00	13.00	13.00	14.00	15.00	13.00	11.00
Liabilities	-22.0%	75.00	96.00	75.00	73.00	79.00	75.00	75.00	93.00	94.00	86.00	81.00	45.00	47.00	50.00	45.00	52.00	53.00	51.00	48.00	75.00	59.00
Current Liabilities	-33.6%	31.00	47.00	32.00	29.00	34.00	33.00	34.00	42.00	40.00	31.00	27.00	34.00	39.00	41.00	36.00	43.00	52.00	50.00	47.00	56.00	58.00
Shareholder's Equity	-6.8%	121	129	151	176	194	218	242	265	287	310	325	339	348	195	204	93.00	99.00	107	111	117	-
Retained Earnings	-2.8%	-481	-468	-442	-413	-389	-360	-329	-302	-275	-247	-226	-209	-194	-181	-168	-158	-149	-140	-133	-127	-115
Additional Paid-In Capital	0.7%	602	598	594	589	583	579	573	569	563	558	552	548	543	377	372	252	249	247	245	244	9.00
Shares Outstanding	1.8%	51.00	50.00	49.00	49.00	47.00	47.00	46.00	46.00	45.00	44.00	44.00	43.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	90,600	-	-	-	156	-	-	-	900	-	-	-	248	-	-	-	513	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-52.1%	-20,413	-13,418	-16,681	-10,414	-15,745	-16,762	-14,765	-27,349	-11,357	-15,274	-17,880	-25,931	-11,743	-2,532	-16,124	-15,354	-8,643	2,405	-9,638	-10,902	66.00
Share Based Compensation	-20.7%	2,687	3,389	3,482	3,485	3,695	5,787	4,415	4,415	4,816	4,032	3,689	3,600	3,057	3,477	1,690	1,822	1,249	1,201	1,402	1,646	609
Cashflow From Investing	154.1%	6,301	-11,638	-8,605	19,549	13,793	21,851	10,826	23,021	-3,161	39,911	29,669	-47,105	-82,544	-63,140	5,647	-7,615	-35.00	-34,848	-43,930	-1,841	-960
Cashflow From Financing	-88.5%	1,129	9,816	290	-	-	511	760	-420	515	1,347	-506	6,010	162,849	941	118,683	1,321	323	471	-22,686	142,777	14,386

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PSNL Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Revenue	$ 73,481	$ 65,047	$ 85,494
Costs and expenses
Cost of revenue	55,273	51,697	53,837
Research and development	64,776	64,912	49,312
Selling, general and administrative	49,726	63,969	47,698
Lease impairment	5,565
Restructuring and other charges	8,077
Total costs and expenses	183,417	180,578	150,847
Loss from operations	(109,936)	(115,531)	(65,353)
Interest income	5,901	2,396	367
Interest expense	(110)	(201)	(184)
Other income (expense), net	(4,068)	61	(42)
Loss before income taxes	(108,213)	(113,275)	(65,212)
Provision for income taxes	83	40	14
Net loss	$ (108,296)	$ (113,315)	$ (65,226)
Net loss per share, basic	$ (2.25)	$ (2.48)	$ (1.49)
Net loss per share, diluted	$ (2.25)	$ (2.48)	$ (1.49)
Weighted-average shares outstanding, basic	48,175,201	45,704,805	43,886,730
Weighted-average shares outstanding, diluted	48,175,201	45,704,805	43,886,730

PSNL Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 56,984	$ 89,128
Short-term investments	57,195	78,530
Accounts receivable, net	17,730	16,642
Inventory and other deferred costs	10,474	8,591
Prepaid expenses and other current assets	4,361	6,808
Total current assets	146,744	199,699
Property and equipment, net	57,366	61,935
Operating lease right-of-use assets	17,852	26,480
Other long-term assets	3,137	4,586
Total assets	225,099	292,700
Current liabilities
Accounts payable	14,920	12,854
Accrued and other current liabilities	23,941	19,013
Contract liabilities	3,288	1,264
Short-term warrant liability	5,085
Total current liabilities	47,234	33,131
Long-term operating lease liabilities	38,321	41,041
Long-term warrant liability	4,942
Other long-term liabilities	5,161	389
Total liabilities	95,658	74,561
Commitments and contingencies (Note 11)
Stockholders’ equity
Common stock, $0.0001 par value - 200,000,000 shares authorized; 50,480,694 and 46,707,084 shares issued and outstanding, respectively	5	5
Additional paid-in capital	598,364	579,456
Accumulated other comprehensive loss	(222)	(912)
Accumulated deficit	(468,706)	(360,410)
Total stockholders’ equity	129,441	218,139
Total liabilities and stockholders’ equity	$ 225,099	$ 292,700

About Personalis Inc

Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test to optimize therapy selection and match patients to clinical trials; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications, such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves pharmaceutical, biopharmaceutical, diagnostic testing, and biotechnology companies; healthcare providers; universities; non-profits; and government entities. The company was incorporated in 2011 and is headquartered in Fremont, California.

CEO	Mr. Christopher M. Hall
WEBSITE	personalis.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	395

Personalis Inc Frequently Asked Questions

What is the ticker symbol for Personalis Inc? What does PSNL stand for in stocks?

PSNL is the stock ticker symbol of Personalis Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Personalis Inc (PSNL)?

As of Thu May 09 2024, market cap of Personalis Inc is 85.7 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PSNL stock?

You can check PSNL's fair value in chart for subscribers.

What is the fair value of PSNL stock?

You can check PSNL's fair value in chart for subscribers. The fair value of Personalis Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Personalis Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PSNL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Personalis Inc a good stock to buy?

The fair value guage provides a quick view whether PSNL is over valued or under valued. Whether Personalis Inc is cheap or expensive depends on the assumptions which impact Personalis Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PSNL.

What is Personalis Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 09 2024, PSNL's PE ratio (Price to Earnings) is -0.93 and Price to Sales (PS) ratio is 1.16. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PSNL PE ratio will change depending on the future growth rate expectations of investors.